Mesenchymal stromal cells (MSCs) are a subset of heterogeneous non-hematopoietic
fibroblast-like cells that can differentiate into cells of multiple lineages, such as …

Mesenchymal stem cells (MSCs) are among the most frequently used cell type for
regenerative medicine. A large number of studies have shown the beneficial effects of MSC …

Ischaemic heart disease is a leading cause of death worldwide. Injury to the heart is
followed by loss of the damaged cardiomyocytes, which are replaced with fibrotic scar …

Administration of mesenchymal stem cells (MSCs) to diseased hearts improves cardiac
function and reduces scar. These effects occur via stimulation of endogenous repair …

Heart failure is a global problem with an estimated prevalence of 38 million patients
worldwide, a number that is increasing with the ageing of the population. It is the most …

Aims CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II
trial designed to determine whether treatment with autologous bone marrow‐derived …

Context Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic
cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible; …

A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Despite substantial clinical advances over the past 65 years, cardiovascular disease
remains the leading cause of death in America. The past 15 years has witnessed major …

Mesenchymal stem cells (MSCs) are broadly distributed cells that retain postnatal capacity
for self-renewal and multilineage differentiation. MSCs evade immune detection, secrete an …